Modifi Biosciences Acquired by Merck
23. Oktober 2024 07:05 ET
|
Modifi Biosciences
NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today...
Cybrexa Regains Rights to CBX-12
06. Februar 2024 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Modifi Bio Raises Additional $4.3 Million in Seed Funding
16. Oktober 2023 07:00 ET
|
Modifi Biosciences
NEW HAVEN, Conn., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced the closing of $4.3 million in a second...
Cybrexa Therapeutics to Debut Preclinical Data Demonstrating CBX-15 is Safe and Highly Efficacious in 13762 Triple Negative Breast Cancer Model at 35th AACR-NCI-EORTC Symposium
10. Oktober 2023 08:05 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Breast Cancer Therapeutics Market to Hit $63.96 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
04. Oktober 2023 05:57 ET
|
The Insight Partners
Pune, India, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Breast cancer is one of the most common types of cancer and has a sizable market for therapies. According to the Centers for Disease Control and...
Prostate Cancer Therapeutics Market Projected to Grow at 6.9% CAGR, Reaching USD 21.7 Billion by 2031: TMR Study
10. Juli 2023 05:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, July 10, 2023 (GLOBE NEWSWIRE) -- The global prostate cancer therapeutics market is projected to expand at a CAGR of 6.9% from 2022 to 2031 to reach US$ 21.7 Bn...
Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12
25. Mai 2023 17:01 ET
|
Cybrexa Therapeutics
Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with CBX-12Dose-Limiting Toxicity Identified as...
Small Cell Lung Cancer Therapeutics Market Value to Exceed of USD 12.9 Bn by 2031, rising at a 11.9% CAGR: TMR Report
05. Mai 2023 12:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, May 05, 2023 (GLOBE NEWSWIRE) -- The global small cell lung cancer therapeutics market was valued at USD 4.6 Bn in 2022 and is projected to expand at a CAGR of...
Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations
12. April 2023 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., April 12, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Breast Cancer Therapeutics Market Exhibits 13.1% CAGR to hit USD 55.27 Billion by 2027
23. Februar 2023 00:45 ET
|
Fortune Business Insights
Pune, India, Feb. 23, 2023 (GLOBE NEWSWIRE) -- The global Breast Cancer Therapeutics Market size was valued at USD 21.58 billion in 2019. The market is projected to grow USD 55.27 billion by 2027,...